Physician profile
Mark Austenfeld
NPI 1801846910
$1,050.95
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $14.02 · 2022: $35.92 · 2023: $34.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $288.58 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $226.17 | 2019 | |
| Janssen Biotech, INC. | $197.03 | 2019 | |
| Blue Earth Diagnostics | $74.34 | 2019 | |
| Abbvie INC. | $49.80 | 2019 | |
| Allergan, INC. | $38.47 | 2019 | |
| Boston Scientific Corporation | $28.79 | 2019-2022 | |
| Coloplast Corp | $22.83 | 2019 | |
| Procept Biorobotics Corporation | $22.58 | 2022 | |
| Olympus America INC. | $19.62 | 2023 | Olympus |
| C. R. Bard, INC. & Subsidiaries | $14.94 | 2019 | |
| Axonics, INC. | $14.44 | 2023 | Bulkamid |
| Rochester Medical Corporation | $14.40 | 2019 | |
| Travere Therapeutics, INC. | $14.02 | 2020 | |
| Merck Sharp & Dohme LLC | $12.96 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Austenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.